Info

(GIP?, PACAP?, others?)

Restoration of lack of biphasic insulin secretion

Yes (Exanatide)

Not tested

Counterregulation by glucagon preserved in hypoglycemia

Yes

Not tested

Inhibition of gastric emptying

Yes

Marginal

Effect on body weight

Weight loss

Weight neutral

Predominant adverse effects

Nausea

None

Mode of administration

Subcutaneous

Oral

useful in slowing the progression of type 2 diabetes or to be used as anti-obesity agents due to their effects on body weight and beta-cell mass and function (88), but here lifestyle intervention and metformin are also effective (89). Incretin mimetics have the advantage of exclusively activating the GLP-1 receptor and therefore exerting exclusively the desired GLP-1-like effects (Table 1) in comparison to DPP-4 inhibitors. DPP-4 inhibitors have the benefit of being oral (and maybe less costly) agents, but their multiple effects besides raising endogenous GLP-1 concentrations are currently not completely elucidated (81). So far, only data from clinical trials covering a timeframe of 1 to 2 years are available. Long-term effects of GLP-1 analogs, incretin mimetics and DPP-4 inhibitors, e.g., on beta-cell proliferation and on the brain have to be followed in clinical practice (90).

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment